22649-37-2

Basic information

• Product Name: 1-AMINO-CYCLOPENTANECARBOXYLIC ACID ETHYL ESTER HCL
• Synonyms: 1-AMINO-CYCLOPENTANECARBOXYLIC ACID ETHYL ESTER HCL;Ethyl 1-aminocyclopentanecarboxylate hydrochloride;Cyclopentanecarboxylic acid, 1-aMino-, ethyl ester, hydrochloride;1-Amino-cyclopentanecarboxylic acid ethyl ester hydrochloride;Ethyl 1-amino-cyclopentanecarboxylate HCl;ADFASIQRQWKXSJ-UHFFFAOYSA-N
• CAS NO: 22649-37-2
• Molecular Formula: C₈H₁₆NO₂*Cl
• Molecular Weight: 193.67
• Product Categories: pharmacetical
• Mol File: 22649-37-2.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-AMINO-CYCLOPENTANECARBOXYLIC ACID ETHYL ESTER HCL(CAS DataBase Reference)
• NIST Chemistry Reference: 1-AMINO-CYCLOPENTANECARBOXYLIC ACID ETHYL ESTER HCL(22649-37-2)
• EPA Substance Registry System: 1-AMINO-CYCLOPENTANECARBOXYLIC ACID ETHYL ESTER HCL(22649-37-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 22649-37-2(Hazardous Substances Data)

Usage

General Description

1-AMINO-CYCLOPENTANECARBOXYLIC ACID ETHYL ESTER HCL is a chemical compound that is a salt of the amino acid cyclopentanecarboxylic acid ethyl ester. It is commonly used in the synthesis of pharmaceuticals and as a building block for drug molecules. The HCL salt form of this compound is commonly used for ease of handling and storage, as well as for improved solubility in aqueous solutions. 1-AMINO-CYCLOPENTANECARBOXYLIC ACID ETHYL ESTER HCL is an important intermediate in organic synthesis and pharmaceutical research, and its properties make it a valuable tool for the development of new drugs and therapeutic agents.

Upstream product

• 64-17-5 ethanol 
• 52-52-8 1-amino-1-cyclopentanecarboxylic acid 
• 110-52-1 1,4-dibromo-butane 

Downstream Products

• 17193-28-1 1-aminocyclopentane-1-carboxamide 
• 93948-00-6 1-N-carbobenzyloxyglycylamino-1-ethoxycarbonylcyclopentane 
• 840506-50-5 phenyl (ethyloxy-L-cyclopentylglycinyl)phosphorochloridate 
• 90392-32-8 6,9-diaza-7,10-dioxospiro<4,5>decane 
• 145122-50-5 1-(2,4-difluorophenyl)-6-fluoro-7-(6,9-diazaspiro<4,5>decan-9-yl)-1,4-dihydro-4-oxo<1,8>naphthyridine-3-carboxylic acid trifluoroacetic acid salt 
• 145122-48-1 1-(2,4-difluorophenyl)-6-fluoro-7-(6,9-diazaspiro<4,5>decan-9-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid hydrochloride 
• 145122-71-0 ethyl 1-(2,4-difluorophenyl)-6-fluoro-7-(6,9-diazaspiro<4,5>decan-9-yl)-1,4-dihydro-4-oxo<1,8>naphthyridine-3-carboxylate 
• 145122-70-9 ethyl 1-(2,4-difluorophenyl)-6-fluoro-7-(6,9-diazaspiro<4,5>decan-9-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylate 
• 145122-55-0 6,9-diazaspiro<4,5>decane dihydrochloride 

Relevant articles and documents

SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES

The present invention relates to polysubstituted imidazolone derivatives, to the pharmaceutical compositions comprising them and to the therapeutic uses thereof in the human and animal health fields. The present invention also relates to a process for preparing these derivatives.

CHEMICAL COMPOUNDS

Phosphoramidate derivatives of nucleotides and their use in the treatment of cancer are described. The base moieties of, for example, each of deoxyuridine, cytarabine, gemcitabine and citidine may be substituted at the 5-position. The phosphoramidate moiety has attached to the P atom an aryl-O moiety and an α-amino acid moiety. The α-amino acid moiety may correspond to or be derived from either a naturally occurring or a non-naturally occurring amino acid.

Composition for the treatment of damaged tissue

A pharmaceutical for use in damaged tissue, such as wound, treatment (e.g. healing) is described. The pharmaceutical comprising a composition which comprises: (a) a growth factor; and (b) an inhibitor agent; and optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.